What is an inhibitor of integrame?
Integrase inhibitor is a new class of anti-HIV drugs that focuses on enzyme integrase. At the beginning of 2010, one member of this class was approved for commercial use in the United States. Raltegravir, also known as ISENTRESS®, has advanced in the treatment of HIV infection because it focuses on the step of a disease that was previously considered unlimited. Another advantage is that it can be used in people who have developed resistance to other types of anti-hiv drugs. This drug was approved for use in the United States in October 2007. Its genetic material is in the form of RNA, not DNA. It uses an enzyme, a molecule that catalyzes reactions called reverse transcriptase to copy RNA to viral DNA. He puts his bottom into the bottom of the host, where it spreads as if it belonged to human cells. It infects cells that work to warn foreign attackers, so that the body does not connect an effective response to the virus.
Without treatment, the virus proliferates in the absence of a functional immune system. It was that HIV almost always advanced to AIDS, which generally led to death. The drugs used to treat retroviral infections are known as antiretroviral drugs and their development was a revolution in the treatment of HIV. The mortality rate of individuals infected with this virus has been significantly reduced since the use of these drugs. One of the problems with this treatment, however, was the development of resistance to the virus on multiple antiretroviral drugs.
These types of drugs affect different steps in the life cycle of the virus, especially several enzymes that participate in the HIV molecule process infecting its host of human cells. The previous treatment enzymes was reverse transcriptase and protease that cleaves proteins. Resistance has evolved for both of these mechanisms. Thus, the development of an inhibitor of integrame is of great importance for HIV treatment because it focuses on a completely different step.
It is a step in inserting into the bottom of the host that is focused inHibitor of integrame. There are three phases of integrade activities. First, the integrage binds the bottom of the cell. It also prepares a viral DNA to integrate by mixing the change of its DNA for its preparation for advertising. Then the processed DNA is inserted into the host cell, which will now change for the purpose of producing the virus particles.
The original research of the development of integrame inhibitors was not successful, but primarily focused on the first two steps. Raltegravir focuses on the third step. With integration into a host cell blocked virus cannot spread. This gives the patient's immune system a chance to recover.
Standard treatment for the use of antiretroviral drug to treat HIV infection is the use of multiple drugs. At least three drugs are generally used simultaneously. The Food and Drug Administration (FDA) has approved Raltegravir for the use of people who already use other anti-HIV medicines. It has been shown to work well with other drugs and for people who have developed resistance to other treatment. Raltegravir is not approved for people who are newlyinfected HIV.
This inhibitor of integrame is taken as a pill, usually twice a day. Ordinary side effects are nausea, diarrhea, fever and headache. In the United States known as Elitegravir, there is another medicine in advanced clinical trials. It is possible that another integrase inhibitor will soon be available for HIV treatment.